Gyre Therapeutics, Inc. GYRE Open Gyre Therapeutics, Inc. in new tab
Gyre Therapeutics, Inc. Analysis (GYRE)
Is Gyre Therapeutics, Inc. a good investment? Gyre Therapeutics, Inc. (GYRE) is currently trading at 6.44 USD. Market analysts have a consensus price target of 18.67 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 385.50. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Gyre Therapeutics, Inc. is expected to release its next earnings report on Aug. 10, 2026. The market consensus estimate for Forward EPS is 0.06.
Investor FAQ
Does Gyre Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Gyre Therapeutics, Inc.?
Gyre Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 10, 2026. The company currently has a trailing EPS of -0.08.
Company Profile
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2023 | 0.24 USD |
| Jan. 13, 2023 | 0.2400 |
| 2022 | 1.43 USD |
| Sept. 21, 2022 | 1.4300 |
| 2015 | 0.57 USD |
| Aug. 20, 2015 | 0.5690 |
Yearly aggregated dividends
Dividends
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 31, 2023 | 0.070000 |
| Feb. 13, 2017 | 0.070000 |
| Oct. 31, 2023 | 0.070000 |
| Feb. 13, 2017 | 0.070000 |
| Oct. 31, 2023 | 0.070000 |
| Feb. 13, 2017 | 0.070000 |
| Oct. 31, 2023 | 0.070000 |
| Feb. 13, 2017 | 0.070000 |
| Aug. 21, 2015 | 0.142857 |
| Feb. 13, 2017 | 0.066667 |
| Oct. 31, 2023 | 0.066667 |
| Oct. 31, 2023 | 0.070000 |
| Feb. 13, 2017 | 0.070000 |
| Aug. 21, 2015 | 0.140000 |
| Oct. 31, 2023 | 0.070000 |
| Feb. 13, 2017 | 0.070000 |
| Oct. 31, 2023 | 0.070000 |
| Feb. 13, 2017 | 0.070000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion